Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Postmarket

Last Trade
Delayed
$1.20
-0.02 (-1.64%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.22
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.26
Day's Low
1.18
Volume
(Light)
Volume:
3,095,769

10-day average volume:
4,789,899
3,095,769

Elsevier Signs Collaboration to Develop Novel Prediction Tool to Reduce Drug Development Safety Risk

3:00 am ET October 22, 2020 (PR Newswire) Print

Elsevier, a global information analytics business specializing in science and health, today announced its collaboration with the pharmaceutical company Novartis to develop a safety margin risk assessment prediction tool, largely using PharmaPendium data.

https://mma.prnewswire.com/media/754760/Elsevier_Logo.jpg

The FDA estimates more than 106,000 people die every year due to adverse drug reactions (ADRs); in the U.S. alone, the cost to the medical care system is an estimated $200 billion per year. Unanticipated drug safety concerns often stem from off-target drug activity and are a major cause for drug attrition during drug development, including many post-market drug withdrawals. The new solution from Elsevier and Novartis is expected to enable the most comprehensive target profiling and clinical interpretation due to the combination of deep scientific data curation and technological expertise. Mitigating safety liabilities early on in drug development helps to select promising candidates early, optimize drug design and avoid late stage failures.

Key to predicting the clinical significance of potential off-target toxicity is the estimation of the drug safety margin for a specific target. To generate safety margin estimates for a broad set of targets, researchers need the context of clinical data from marketed and withdrawn drugs. They also need to navigate the challenges of identifying reliable test systems that can lead to proper translational safety assessment. Performing this today requires researchers to manually mine literature and regulatory documents for drug safety and pharmacokinetic data, which is laborious, and thus limits the number of targets for which safety margin estimates are made.

As highlighted in a 2015 FDA publication, there is a need for better justification around target selection related to human safety, interpretation of clinical significance, and early submission of this data in order to monitor and mitigate safety risks throughout clinical drug development. The collaboration between Elsevier and Novartis seeks to address this need, in order to also make drug submissions and communications with regulatory agencies more effective and efficient.

"Drug safety issues are one of the major causes of late-stage drug failure in pharmaceutical development, and the new solution we are developing is designed to help drug development teams avoid this outcome," said Cameron Ross, Managing Director Life Sciences Solutions, Elsevier. "We are looking forward to combining our skills with those of the Novartis team, to accelerate R&D. Providing the most comprehensive resource for off-target risk assessments that can be used as early as lead optimization will help researchers build confidence in critical go/no-go decisions."

PharmaPendium provides users with fully searchable drug approval documents and extracted data to inform critical drug development decisions. To find out more, please visit: https://www.elsevier.com/en-gb/solutions/pharmapendium-clinical-data

About Elsevier

Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we're committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com

Media contactDavid Tucker+44 (0)7920 536 160 d.tucker@elsevier.com

https://c212.net/c/img/favicon.png?sn=IO65971&sd=2020-10-22

View original content:http://www.prnewswire.com/news-releases/elsevier-signs-collaboration-to-develop-novel-prediction-tool-to-reduce-drug-development-safety-risk-301157110.html

SOURCE Elsevier

https://rt.prnewswire.com/rt.gif?NewsItemId=IO65971&Transmission_Id=202010220300PR_NEWS_USPR_____IO65971&DateId=20201022

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.